Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

42 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
The Safety and Immunogenicity of the BNT162b2 mRNA COVID-19 Vaccine in Japanese Patients after Allogeneic Stem Cell Transplantation.
Watanabe M, Yakushijin K, Funakoshi Y, Ohji G, Hojo W, Sakai H, Saeki M, Hirakawa Y, Matsumoto S, Sakai R, Nagao S, Kitao A, Miyata Y, Koyama T, Saito Y, Kawamoto S, Ito M, Murayama T, Matsuoka H, Minami H. Watanabe M, et al. Among authors: ohji g. Vaccines (Basel). 2022 Jan 21;10(2):158. doi: 10.3390/vaccines10020158. Vaccines (Basel). 2022. PMID: 35214617 Free PMC article.
Massive surge of mRNA expression of clonal B-cell receptor in patients with COVID-19.
Funakoshi Y, Ohji G, Yakushijin K, Ebisawa K, Arakawa Y, Saegusa J, Matsumoto H, Imanishi T, Fukuda E, Matsutani T, Mori Y, Iwata K, Minami H. Funakoshi Y, et al. Among authors: ohji g. Heliyon. 2021 Aug;7(8):e07748. doi: 10.1016/j.heliyon.2021.e07748. Epub 2021 Aug 10. Heliyon. 2021. PMID: 34395931 Free PMC article.
Limited increase in antibody titers following mRNA SARS-CoV-2 vaccination for more than 3 years after final dose of anti-CD20 antibody.
Funakoshi Y, Yakushijin K, Ohji G, Hojo W, Sakai H, Watanabe M, Saeki M, Hirakawa Y, Sakai R, Matsumoto S, Mizutani Y, Kitao A, Miyata Y, Saito Y, Kawamoto S, Yamamoto K, Ito M, Nishimura M, Imamura Y, Kiyota N, Matsuoka H, Mori Y, Minami H. Funakoshi Y, et al. Among authors: ohji g. Int J Hematol. 2022 Jan;115(1):7-10. doi: 10.1007/s12185-021-03247-y. Epub 2022 Jan 4. Int J Hematol. 2022. PMID: 34981433 Free PMC article.
Safety and immunogenicity of the COVID-19 vaccine BNT162b2 in patients undergoing chemotherapy for solid cancer.
Funakoshi Y, Yakushijin K, Ohji G, Hojo W, Sakai H, Takai R, Nose T, Ohata S, Nagatani Y, Koyama T, Kitao A, Nishimura M, Imamura Y, Kiyota N, Harada K, Tanaka Y, Mori Y, Minami H. Funakoshi Y, et al. Among authors: ohji g. J Infect Chemother. 2022 Apr;28(4):516-520. doi: 10.1016/j.jiac.2021.12.021. Epub 2021 Dec 30. J Infect Chemother. 2022. PMID: 35090826 Free PMC article.
Promising Efficacy of a Third Dose of mRNA SARS-CoV-2 Vaccination in Patients Treated with Anti-CD20 Antibody Who Failed 2-Dose Vaccination.
Funakoshi Y, Yakushijin K, Ohji G, Hojo W, Sakai H, Watanabe M, Kitao A, Miyata Y, Saito Y, Kawamoto S, Yamamoto K, Ito M, Koyama T, Imamura Y, Kiyota N, Matsuoka H, Mori Y, Minami H. Funakoshi Y, et al. Among authors: ohji g. Vaccines (Basel). 2022 Jun 17;10(6):965. doi: 10.3390/vaccines10060965. Vaccines (Basel). 2022. PMID: 35746573 Free PMC article.
A Third Dose COVID-19 Vaccination in Allogeneic Hematopoietic Stem Cell Transplantation Patients.
Watanabe M, Yakushijin K, Funakoshi Y, Ohji G, Ichikawa H, Sakai H, Hojo W, Saeki M, Hirakawa Y, Matsumoto S, Sakai R, Nagao S, Kitao A, Miyata Y, Koyama T, Saito Y, Kawamoto S, Yamamoto K, Ito M, Murayama T, Matsuoka H, Minami H. Watanabe M, et al. Among authors: ohji g. Vaccines (Basel). 2022 Oct 29;10(11):1830. doi: 10.3390/vaccines10111830. Vaccines (Basel). 2022. PMID: 36366338 Free PMC article.
42 results